A real-world, multicenter study of atezolizumab plus bevacizumab in viral and non-viral advanced hepatocellular carcinoma patients from Asia and Europe

被引：0

作者：

Rossari, F. ^{[1
]}

Tada, T. ^{[2
]}

Shimose, S. ^{[3
]}

Kudo, M. ^{[4
]}

Yoo, C. ^{[5
]}

Cheon, J. ^{[6
]}

Finkelmeier, F. ^{[7
]}

Lim, H. Y. ^{[8
]}

Presa, J. ^{[9
]}

Masi, G. ^{[10
]}

Bergamo, F. ^{[11
]}

Amadeo, E. ^{[12
]}

Vitiello, F. ^{[13
]}

Foti, S. ^{[14
]}

Camera, S. ^{[12
]}

Persano, M. ^{[15
]}

Stefanini, B. ^{[16
]}

Scartozzi, M. ^{[17
]}

Rimini, M. ^{[12
]}

Gardini, A. Casadei ^{[12
]}

机构：

[1] UniSR Univ Vita & Salute San Raffaele Milano, Dept Med Oncol, SR Tiget, Milan, Italy

[2] Japanese Red Cross Soc Himeji Hosp, Internal Med, Himeji, Japan

[3] Kurume Univ Hosp, Div Gastroenterol, Dept Med, Kurume, Japan

[4] Kindai Univ, Dept Gastroenterol & Hepatol, Fac Med, Osaka, Japan

[5] Univ Ulsan, Dept Med Oncol, Asan Med Ctr, Seoul, South Korea

[6] Ulsan Univ Hosp, Div Hematol & Oncol, Ulsan, South Korea

[7] Goethe Univ Frankfurt am Main, Gastroenterol Dept, Campus Westend, Frankfurt, Germany

[8] Sungkyunkwan Univ, Dept Med, Samsung Med Ctr SMC, Sch Med, Seoul, South Korea

[9] Ras os Montes & Alto Douro Hosp Ctr, Liver Unit, Vila Real, Portugal

[10] Pisa Univ, Dept Translat Res & New Technol Med & Surg, Pisa, Italy

[11] IOV Ist Oncol Veneto IRCCS, Oncol 1, Padua, Italy

[12] IRCCS Osped San Raffaele, Dept Med Oncol, Milan, Italy

[13] IRCCS Osped San Raffaele, Oncol, Milan, Italy

[14] IRCCS Osped San Raffaele, Dept Oncol, Milan, Italy

[15] AOU Cagliari Osped Civile, Dept Med Oncol, Cagliari, Italy

[16] Imperial Coll London, Oncol, Hammersmith Campus, London, England

[17] Univ Cagliari, Dept Med Oncol, Cagliari, Italy

来源：

ANNALS OF ONCOLOGY | 2024年 / 35卷

关键词：

D O I：

10.1016/j.annonc.2024.05.191

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

182P

引用

页码：S82 / S82

页数：1

共 50 条

[1] Safety and Efficacy of Atezolizumab-Bevacizumab in Non-Viral and Viral Etiologies of Hepatocellular Carcinoma: A Multicenter Retrospective Comparative Study
Kulkarni, Anand
Kumar, Karan
Sharma, Mithun
Shaik, Sameer
Iyengar, Sowmya
Venishetty, Shantan
Alla, Manasa
Saraswat, Vivek
Padaki, Nagaraja
Reddy, Nageshwar
JOURNAL OF HEPATOLOGY, 2024, 80 : S454 - S454
[2] Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non-viral infection: A Japanese multicenter observational study
Hatanaka, Takeshi
Kakizaki, Satoru
Hiraoka, Atsushi
Tada, Toshifumi
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Shimada, Noritomo
Kawata, Kazuhito
Kosaka, Hisashi
Tanaka, Takaaki
Ohama, Hideko
Nouso, Kazuhiro
Morishita, Asahiro
Tsutsui, Akemi
Nagano, Takuya
Itokawa, Norio
Okubo, Tomomi
Arai, Taeang
Imai, Michitaka
Naganuma, Atsushi
Koizumi, Yohei
Nakamura, Shinichiro
Joko, Kouji
Kaibori, Masaki
Iijima, Hiroko
Hiasa, Yoichi
Kumada, Takashi
CANCER MEDICINE, 2023, 12 (05): : 5293 - 5303
[3] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano
Margherita Rimini
Toshifumi Tada
Goki Suda
Shigeo Shimose
Masatoshi Kudo
Jaekyung Cheon
Fabian Finkelmeier
Ho Yeong Lim
Lorenza Rimassa
José Presa
Gianluca Masi
Changhoon Yoo
Sara Lonardi
Francesco Tovoli
Takashi Kumada
Naoya Sakamoto
Hideki Iwamoto
Tomoko Aoki
Hong Jae Chon
Vera Himmelsbach
Tiziana Pressiani
Takumi Kawaguchi
Margarida Montes
Caterina Vivaldi
Caterina Soldà
Fabio Piscaglia
Atsushi Hiraoka
Takuya Sho
Takashi Niizeki
Naoshi Nishida
Christoph Steup
Massimo Iavarone
Giovanni Di Costanzo
Fabio Marra
Mario Scartozzi
Emiliano Tamburini
Giuseppe Cabibbo
Francesco Giuseppe Foschi
Marianna Silletta
Masashi Hirooka
Kazuya Kariyama
Joji Tani
Masanori Atsukawa
Koichi Takaguchi
Ei Itobayashi
Shinya Fukunishi
Kunihiko Tsuji
Toru Ishikawa
Kazuto Tajiri
Journal of Cancer Research and Clinical Oncology, 2023, 149 : 5591 - 5602
[4] Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Persano, Mara
Rimini, Margherita
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Rimassa, Lorenza
Presa, Jose
Masi, Gianluca
Yoo, Changhoon
Lonardi, Sara
Tovoli, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Pressiani, Tiziana
Kawaguchi, Takumi
Montes, Margarida
Vivaldi, Caterina
Solda, Caterina
Piscaglia, Fabio
Hiraoka, Atsushi
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Iavarone, Massimo
Di Costanzo, Giovanni
Marra, Fabio
Scartozzi, Mario
Tamburini, Emiliano
Cabibbo, Giuseppe
Foschi, Francesco Giuseppe
Silletta, Marianna
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (09) : 5591 - 5602
[5] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study
Rimini, M.
Rimassa, L.
Kudo, M.
Shigeo, S.
Toshifumi, T.
Suda, G.
Yoo, C.
Cheon, J.
Lonardi, S.
Scartozzi, M.
Tamburini, E.
Masi, G.
Cascinu, S.
Casadei-Gardini, A.
ANNALS OF ONCOLOGY, 2022, 33 : S362 - S363
[6] Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: An international study.
Casadei-Gardini, Andrea
Rimini, Margherita
Rimassa, Lorenza
Burgio, Valentina
Kudo, Masatoshi
Tada, Toshifumi
Shimose, Shigeo
Suda, Goki
Yoo, Changhoon
Cheon, Jaekyng
Pinato, David J. James
Scartozzi, Mario
Cascinu, Stefano
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: A real-world, multicenter study
Rossari, F.
Tada, T.
Shimose, S.
Kudo, M.
Yoo, C.
Cheon, J.
Finkelmeier, F.
Lim, H. Y.
Presa, J.
Masi, G.
Bergamo, F.
Amadeo, E.
Vitiello, F.
Foti, S.
Persano, M.
Piscaglia, F.
Scartozzi, M.
Cascinu, S.
Rimini, M.
Gardini, A. Casadei
ANNALS OF ONCOLOGY, 2023, 34 : S1547 - S1547
[8] Disease etiology impact on outcomes of hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a real-world, multicenter study
Rossari, Federico
Tada, Toshifumi
Suda, Goki
Shimose, Shigeo
Kudo, Masatoshi
Yoo, Changhoon
Cheon, Jaekyung
Finkelmeier, Fabian
Lim, Ho Yeong
Presa, Jose
Masi, Gianluca
Bergamo, Francesca
Amadeo, Elisabeth
Vitiello, Francesco
Kumada, Takashi
Sakamoto, Naoya
Iwamoto, Hideki
Aoki, Tomoko
Chon, Hong Jae
Himmelsbach, Vera
Iavarone, Massimo
Cabibbo, Giuseppe
Montes, Margarida
Foschi, Francesco Giuseppe
Vivaldi, Caterina
Solda, Caterina
Sho, Takuya
Niizeki, Takashi
Nishida, Naoshi
Steup, Christoph
Hirooka, Masashi
Kariyama, Kazuya
Tani, Joji
Atsukawa, Masanori
Takaguchi, Koichi
Itobayashi, Ei
Fukunishi, Shinya
Tsuji, Kunihiko
Ishikawa, Toru
Tajiri, Kazuto
Ochi, Hironori
Yasuda, Satoshi
Toyoda, Hidenori
Ogawa, Chikara
Nishimura, Takashi
Hatanaka, Takeshi
Kakizaki, Satoru
Shimada, Noritomo
Kawata, Kazuhito
Hiraoka, Atsushi
LIVER CANCER, 2024, 13 (05) : 522 - 536
[9] Effectiveness and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: A multicenter, retrospective real-world study in China
Zhang, Hui
Shao, Minghua
Tan, Binbin
Fu, Yin
Yuan
Chen, Hailei
CANCER RESEARCH, 2024, 84 (06)
[10] Atezolizumab and bevacizumab in advanced hepatocellular carcinoma: Real-world data.
Bezalel, Nomi
Davidov, Yana
Likhter, Mariya
Ezra, Oranit Cohen
Inbar, Yael
Halpern, Naama
Ben Boursi
Beller, Tamar
Pery, Ron
Shmueli, Einat S.
Nachmany, Ido
Ben Ari, Ziv
Margalit, Ofer
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →